Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study

•Rheumatic patients are at risk of developing infections because their immunocompromised state.•Biologics or small-molecules would not appear to be related to increased or reduced susceptibility of COVID-19.•DMARDS (traditional and biologics) and small molecules can be probably used at different timings of the disease.•The use of immunosuppressant for prophylaxis of COVID-19 is still a matter of debate.•Patient surveillance and the endorsement of extensive preventive barrier measures is mandatory.